You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
translate meditech spreadsheet into bayesDB and query bsql to find win-win strategy for both VC and startup (maximize chance of FDA approval)
spreadsheet model simulates eight scenarios, how can gensql/db assist in finding win win solution for vc maximizing profit and startup maximizing chances of FDA approval given uncertainty in supply chain configuration, cash for FDA approval. Below is prompt provided by startup operations expert (my advisor)
1.what is the best strategy for MediTech? Can they successfully complete FDA approval without changing their strategy (i.e., no in-sourcing, no more funding)? Do you think MediTech should in-source some of the manufacturing, or spend all the cash that the VC has to offer to finance current operations? Is there an optimum balance that can be achieved where all the parties have aligned interests?
2. Do you think MediTech's current path is consistent with a long-term strategy toward mass production?
What alternatives are there?
What are the trade-offs inherent in the operations decisions faced by the company?
How are these decisions different for a startup as opposed to a large corporation?
How might this affect strategy in marketing, design, and engineering?
What would you recommend?
The text was updated successfully, but these errors were encountered:
hyunjimoon
changed the title
eval(PC)1 - Matin
translate meditech spreadsheet into bayesDB with Matin (eval(PC)1)
May 31, 2024
hyunjimoon
changed the title
translate meditech spreadsheet into bayesDB with Matin (eval(PC)1)
translate three casestudies into gen with Matin (eval(PC)1)
Jun 20, 2024
translate meditech spreadsheet into bayesDB and query bsql to find win-win strategy for both VC and startup (maximize chance of FDA approval)
1.what is the best strategy for MediTech? Can they successfully complete FDA approval without changing their strategy (i.e., no in-sourcing, no more funding)? Do you think MediTech should in-source some of the manufacturing, or spend all the cash that the VC has to offer to finance current operations? Is there an optimum balance that can be achieved where all the parties have aligned interests?
2. Do you think MediTech's current path is consistent with a long-term strategy toward mass production?
The text was updated successfully, but these errors were encountered: